MARKET

ATOS

ATOS

Atossa Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.880
+0.010
+0.26%
After Hours: 3.980 +0.1 +2.58% 19:31 08/05 EDT
OPEN
3.870
PREV CLOSE
3.870
HIGH
3.920
LOW
3.830
VOLUME
225.32K
TURNOVER
--
52 WEEK HIGH
5.08
52 WEEK LOW
0.7550
MARKET CAP
35.73M
P/E (TTM)
-2.1983
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ATOS stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.

EPS

ATOS News

More
Atossa on go to start early-stage study of COVID-19 nasal spray
An ethics committee in Australia has signed off on a Phase 1 clinical trial evaluating Atossa Therapeutics' (ATOS +6.6%) AT-301, administered via nasal spr
seekingalpha · 2d ago
Atossa Therapeutics Receives Approval to Open Clinical Study of AT-301 Nasal Spray Being Developed to Treat COVID-19
Enrollment Expected to Begin Within 30 daysSEATTLE, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical
GlobeNewswire · 2d ago
Atossa Therapeutics Highlights Findings From Expanded Access Treatment With Endoxifen: 'Patient has taken Atossa's Endoxifen for 18 months without side effects and without cancer recurrence'
Benzinga · 6d ago
Atossa Therapeutics Announces Findings from FDA-Approved Expanded Access Treatment with Endoxifen
Patient has taken Atossa’s Endoxifen for 18 months without side effects and without cancer recurrenceSEATTLE, July 30, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop
GlobeNewswire · 6d ago
Registration Is Now Open for Atossa Therapeutics’ Tribe Public Webinar Presentation and Q&A Event on July 30, 2020
Atossa’s CEO, Dr. Steven Quay, M.D., Ph.D., will address recent progress with two COVID-19 treatment programsSEATTLE, July 27, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company with a current focus on
GlobeNewswire · 07/27 13:30
Atossa Therapeutics shares are trading higher after Advance Clinical contracted the company's AT-301 Nasal Spray Clinical study.
Benzinga · 07/22 12:18
Atossa Stock at $8 a Share? This 5-Star Analyst Thinks It’s Possible
Shares of Atossa Therapeutics (ATOS) have done what shares of most companies in the hunt for coronavirus solutions have done in 2020 – appreciate. Since the turn of the year, there has been 171% of upside for the Seattle-based biotech firm.Despite the impressi
SmarterAnalyst · 07/22 02:12
Why Atossa Therapeutics Is Trading Lower Today
Atossa Therapeutics (NASDAQ: ATOS) shares are trading lower on Thursday. The company announced it has contracted with Avance Clinical to conduct a clinical study for its AT-301 Nasal Spray for the company's second coronavirus therapeutics development progr
Benzinga · 07/16 14:18

Industry

Biotechnology & Medical Research
+0.15%
Pharmaceuticals & Medical Research
+0.27%

Hot Stocks

Symbol
Price
%Change

About ATOS

Atossa Therapeutics Inc., formerly Atossa Genetics Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics and delivery methods for breast cancer and other breast conditions. Its pipeline includes two programs: endoxifen and intraductal microcatheter technology. It is developing Topical Endoxifen formulation for transdermal delivery. It is developing Topical Endoxifen to address two populations: to reduce mammographic breast density (MBD) and to prevent/reduce gynecomastia in prostate cancer patients starting androgen deprivation therapy. It is also developing oral presentation of endoxifen. It is developing its microcatheter technology to deliver therapeutics through the nipple directly to the site of early breast cancer. It is also developing our proprietary intraductal microcatheter technology for Chimeric Antigen Receptor Therapy (CAR-T).
More

Webull offers kinds of Atossa Therapeutics Inc stock information, including NASDAQ:ATOS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATOS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATOS stock methods without spending real money on the virtual paper trading platform.